^
    Back
    Association details:
    Biomarker:BCL7A overexpression
    Cancer:Glioma
    Drug:temozolomide (DNA synthesis inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    J Transl Med
    Title:

    BCL7A as a novel prognostic biomarker for glioma patients

    Published date:
    08/06/2021
    Excerpt:
    ...we found that BCL7A had no prognostic effect on the overall survival of GBM patients who received IR only; however, patients who received chemotherapy (TMZ) combined with IR in the high BCL7A group survived longer than patients in the low BCL7A group (HR = 0.346, p < 0.05).
    DOI:
    10.1186/s12967-021-03003-0